Job Description:
The statistical genetics group is looking for a highly-skilled candidate who is eager to learn and apply the most novel methods of statistical genetics and machine learning on very large scale genetic data. The successful candidate will participate on the statistical design and analysis of human genetic studies with an emphasis on genome-wide association studies of phenotypes with > 500,000 previously unpublished samples. The candidate should have a foundation in statistics and genetics, a strong work ethic. The position requires excellent written and oral communication skills allowing the preparation of effective reports, presentations and manuscripts. The position offers the opportunity to interact with research biologists, clinicians and computational scientists on complex datasets incorporating genetic, genomic and clinical data. The aims of the main research project which analysis will be lead by the successful candidate are: 1. Identify and characterize novel AD/PD loci using state of the art phenotyping and GWAS in very large studies 2. Identify novel endophenotypes from imaging/cognitive data 3. Use rich endophenotypes to infer mechanism of action of disease loci 4. Use mendelian randomization approaches to evaluate potential therapeutic effect of proposed targets. In Biogen we consider these activities pre-competitive and therefore all the results will be able to be shown in scientific meetings and published in scientific journals. The candidate will be mentored by Dr. Karol Estrada who has a very strong publication record on high impact journals. Qualifications: -Experience in analysis and interpretation of complex disease genetics in large datasets (ideally both GWAS and Next Generation Sequencing studies). -Strong programming skills, as well as a firm grounding in relevant statistical methodologies, will be essential. -Experience processing big data using Distributed File Systems is a plus. Education: PhD in statistics, genomics, human genetics, computer science or related field.
Additional Info:
Alzheimer’s disease and Parkinson’s disease (AD and PD) are the two most common neurodegenerative conditions with known genetic, medical and lifestyle factors that influence risk. There are few, if any, interventions that slow progression in these disorders. Biogen has been ranked as the #1 pharmaceutical institution based on innovation, being AD and PD within our main disease focus. About Biogen Corporate Overview: Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Biogen also manufactures and commercializes biosimilars of advanced biologics. Our global organization of nearly 7,000 employees is committed to a single mission: making a meaningful difference in the lives of patients with few or no treatment options. Biogen was founded in 1978 and today serves patients in nearly 70 countries. A Fortune 500 company, Biogen in 2016 had revenues of $11.4 billion Global headquarters in Cambridge, MA, and international headquarters in Zug, Switzerland Our Science: We aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry. To us, that means creating novel medicines that benefit individuals and society, and bringing new scientific understanding to diseases for which there are no adequate treatments. For nearly two decades Biogen has led in the research and development of new therapies to treat MS, including the most prescribed oral treatment in the world. Now our research is driving revolutionary new MS treatments with the goal of reversing or even repairing damage caused by the disease. We are now applying our neurological expertise to solve some of most challenging and complex diseases of the brain, including Alzheimer’s disease, Parkinson’s disease, and ALS. As we uncover new insights into human biology, Biogen is employing cutting-edge technologies to discover potential treatments for rare and genetic disorders. Biogen is revolutionizing biologics manufacturing, developing the industry’s most advanced plants and processes. This expertise is used to produce both original innovative therapies and biosimilars that expand patient access to lower-cost medicines. Our Corporate Citizenship: The same intellectual discipline and passion that drives our science is reflected in our corporate citizenship, environmental sustainability, and commitment to diversity and inclusion. As a company, we are focused on improving science education and limiting the impact of our company on the environment. In 2015, we became a carbon neutral company and ranked first place on Newsweek’s 2015 Green Rankings, and we are an industry leader on the Dow Jones Sustainability World Index. Biogen was named to Science’s list of Top Employers of 2015 and in 2017 received a perfect score of 100 for the fourth consecutive year on the Human Rights Campaign (HRC) Corporate Equality Index, which also named Biogen as one of its Best Places to Work. All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States. Please be advised that all legitimate correspondence from a Biogen employee will come from "@biogen.com" email accounts. [Click Here to Access the Original Job Post]
The statistical genetics group is looking for a highly-skilled candidate who is eager to learn and apply the most novel methods of statistical genetics and machine learning on very large scale genetic data. The successful candidate will participate on the statistical design and analysis of human genetic studies with an emphasis on genome-wide association studies of phenotypes with > 500,000 previously unpublished samples. The candidate should have a foundation in statistics and genetics, a strong work ethic. The position requires excellent written and oral communication skills allowing the preparation of effective reports, presentations and manuscripts. The position offers the opportunity to interact with research biologists, clinicians and computational scientists on complex datasets incorporating genetic, genomic and clinical data. The aims of the main research project which analysis will be lead by the successful candidate are: 1. Identify and characterize novel AD/PD loci using state of the art phenotyping and GWAS in very large studies 2. Identify novel endophenotypes from imaging/cognitive data 3. Use rich endophenotypes to infer mechanism of action of disease loci 4. Use mendelian randomization approaches to evaluate potential therapeutic effect of proposed targets. In Biogen we consider these activities pre-competitive and therefore all the results will be able to be shown in scientific meetings and published in scientific journals. The candidate will be mentored by Dr. Karol Estrada who has a very strong publication record on high impact journals. Qualifications: -Experience in analysis and interpretation of complex disease genetics in large datasets (ideally both GWAS and Next Generation Sequencing studies). -Strong programming skills, as well as a firm grounding in relevant statistical methodologies, will be essential. -Experience processing big data using Distributed File Systems is a plus. Education: PhD in statistics, genomics, human genetics, computer science or related field.
Requeriments :
Skills :
Areas :
Additional Info:
Alzheimer’s disease and Parkinson’s disease (AD and PD) are the two most common neurodegenerative conditions with known genetic, medical and lifestyle factors that influence risk. There are few, if any, interventions that slow progression in these disorders. Biogen has been ranked as the #1 pharmaceutical institution based on innovation, being AD and PD within our main disease focus. About Biogen Corporate Overview: Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Biogen also manufactures and commercializes biosimilars of advanced biologics. Our global organization of nearly 7,000 employees is committed to a single mission: making a meaningful difference in the lives of patients with few or no treatment options. Biogen was founded in 1978 and today serves patients in nearly 70 countries. A Fortune 500 company, Biogen in 2016 had revenues of $11.4 billion Global headquarters in Cambridge, MA, and international headquarters in Zug, Switzerland Our Science: We aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry. To us, that means creating novel medicines that benefit individuals and society, and bringing new scientific understanding to diseases for which there are no adequate treatments. For nearly two decades Biogen has led in the research and development of new therapies to treat MS, including the most prescribed oral treatment in the world. Now our research is driving revolutionary new MS treatments with the goal of reversing or even repairing damage caused by the disease. We are now applying our neurological expertise to solve some of most challenging and complex diseases of the brain, including Alzheimer’s disease, Parkinson’s disease, and ALS. As we uncover new insights into human biology, Biogen is employing cutting-edge technologies to discover potential treatments for rare and genetic disorders. Biogen is revolutionizing biologics manufacturing, developing the industry’s most advanced plants and processes. This expertise is used to produce both original innovative therapies and biosimilars that expand patient access to lower-cost medicines. Our Corporate Citizenship: The same intellectual discipline and passion that drives our science is reflected in our corporate citizenship, environmental sustainability, and commitment to diversity and inclusion. As a company, we are focused on improving science education and limiting the impact of our company on the environment. In 2015, we became a carbon neutral company and ranked first place on Newsweek’s 2015 Green Rankings, and we are an industry leader on the Dow Jones Sustainability World Index. Biogen was named to Science’s list of Top Employers of 2015 and in 2017 received a perfect score of 100 for the fourth consecutive year on the Human Rights Campaign (HRC) Corporate Equality Index, which also named Biogen as one of its Best Places to Work. All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States. Please be advised that all legitimate correspondence from a Biogen employee will come from "@biogen.com" email accounts. [Click Here to Access the Original Job Post]